Pharmaceuticals

Sinopep

Sinopep released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 552.98 M (forecast CNY 504 M), actual EPS CNY 0.41

Sinopep to Release FY2026 Q1 Earnings on April 30 After-Market (BJT), Forecast Revenue CNY 504 M

Sinopep to Release FY2025 Earnings on April 30 Pre-Market (BJT), Forecast Revenue CNY 2.079 B, EPS CNY 1.69

Sinopep released FY2025 annual earnings on February 27 Pre-Market (BJT), actual revenue CNY 1.943 B (forecast CNY 2.079 B), actual EPS CNY 1.06 (forecast CNY 1.69)

Sinopep released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 415.62 M (forecast CNY 423 M), actual EPS CNY -0.3556

Sinopep released FY2025 9 Months Earnings on October 22 During-Market (BJT), actual revenue CNY 1.527 B, actual EPS CNY 1.417

Sinopep released FY2025 Q3 earnings on October 22 During-Market (BJT), actual revenue CNY 478.9 M (forecast CNY 478 M), actual EPS CNY 0.4299

Sinopep to Release FY2025 Q3 Earnings on October 23 During-Market (BJT), Forecast Revenue CNY 478 M

Sinopep released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue CNY 482.68 M (forecast CNY 592 M), actual EPS CNY 0.497

Sinopep released FY2025 Semi-Annual Earnings on August 20 After-Market (BJT), Actual Revenue: CNY 1.048 B, Actual EPS: CNY 0.9943

Sinopep to Release FY2025 Semi-Annual Earnings on August 21, 2025 (BJT)

ST Nota Receives Pharmaceutical GMP Certificate from Brazil

ST Noate Obtained Registration Certificates for Injection Cetrotide and Agomelatine Tablets

Kaiyuan Securities Recommends Buying Nuotai Biotech

Nortai Bio Penalized by CSRC for Financial Fraud

NuoTai Biologics' Jiande Factory Seven Workshop Commences Production, Adding 2.2 Million Liters of GMP-Level Product Capacity

Noray Bio Receives CSRC Penalty and Will Be ST Listed

Notail Bio's Net Profit Expected to Grow by 32.06% to 45.27% in H1 2025

NuoTai Bio Receives Buy Ratings from Multiple Securities Firms

Nuotai Biopharma Shares Rise, Multiple Brokers Issue Buy Ratings

688076

ST Sinopep announced that the company participated in the bidding organized by the National Organization for Drug Procurement Office for the 11th batch of national centralized drug procurement, and the company's product Agomelatine tablets is expected to be selected in this centralized procurement

Zhitong

ST Sinopep: Agomelatine tablets are expected to be selected for the 11th batch of national centralized drug procurement

According to the Zhitong Finance APP, ST Sinopep released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.527 billion yuan, a year-on-year increase of 21.95%. The net profit attributable to shareholders of the listed company was 445 million yuan, a year-on-year increase of 26.92%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 437 million yuan, a year-on-year increase of 23.20%. The basic earnings per share were 1.42 yuan

Sinopep released its performance for the first three quarters, with a net profit attributable to the parent company of 445 million yuan, an increase of 26.92%

According to the Zhitong Finance APP, ST Sinopep released its third-quarter performance forecast, expecting a net profit attributable to the parent company's owners of 130 million to 140 million yuan in the third quarter of 2025, an increase of 5.62% to 13.74% year-on-year. During the reporting period, the company implemented the business philosophy of "time leading, technology leading," and various main businesses were carried out in an orderly manner, achieving steady growth in net profit

Sinopep expects a profit increase, with an estimated net profit attributable to shareholders of 130 million to 140 million yuan in the third quarter, an increase of 5.62% to 13.74% year-on-year

ST Sinopep released its 2025 semi-annual report, with operating revenue of 1.048 billion yuan, a year-on-year increase of 26.07%; net profit attributable to shareholders was 310 million yuan, a year-on-year increase of 36.49%. The net profit after deducting non-recurring gains and losses was 306 million yuan, a year-on-year increase of 33.49%. Basic earnings per share were 0.99 yuan, mainly benefiting from the growth in sales revenue of peptide raw materials

Sinopep released its half-year performance, with a net profit attributable to the parent company of 310 million yuan, an increase of 36.49%

688105

According to the Qichacha APP, recently, Nanjing Sinopep Biopharmaceutical Co., Ltd. was established with a registered capital of 20 million yuan. The business scope includes: research and development of bio-based material technology; research and development of industrial enzyme preparations; research and development of biological feed; research and development of biochemical products technology, etc. Qichacha's equity penetration shows that the company is jointly held by Sinopep and Vazyme

Vazyme

ST Sinopep, Vazyme and others establish a new biopharmaceutical company

ST Sinopep recently received the drug registration certificates for injectable Acetate of Cetrorelix and Agomelatine tablets approved by the National Medical Products Administration. Acetate of Cetrorelix has unique clinical advantages in assisted reproductive technology, with a fast onset, high safety, and mild injection reactions. Agomelatine, as a new type of antidepressant, has a dual mechanism of action, rapidly improving sleep without affecting daytime function, and has a low risk of sexual dysfunction and good tolerance

ST Sinopep received the drug registration certificate for injectable Acetate of Sunitinib and Agomelatine tablets

Sinopep will be suspended for one day on July 21, 2025, due to receiving the "Advance Notice of Administrative Penalty" from the China Securities Regulatory Commission, and will resume trading on July 22. After resuming, the stock will be subject to other risk warnings, and the A-share abbreviation will be changed to ST Sinopep

Sinopep's stock has been subjected to other risk warnings and will be suspended for trading for 1 day on July 21

688117

01801

601607

02607

China Post Securities stated that although innovative drugs may experience fluctuations in the short term, it holds an optimistic outlook on the market prospects for the next 2-3 years. Recently, the National Healthcare Security Administration released the adjustment plan for the 2025 catalog of innovative drugs for medical insurance and commercial health insurance, clearly supporting innovative drugs, especially the establishment of a commercial insurance catalog for innovative drugs for the first time, providing new payment avenues for high-value innovative drugs. The introduction of this policy combination has stimulated the market for innovative drugs and contributed to the improvement of a multi-level medication security system

SNSW

INNOVENT BIO

Shanghai Pharma

SH PHARMA

Hong Kong Stock Concept Tracking | New Commercial Insurance Innovative Drug Directory Added! 2025 Medical Insurance Directory Adjustment Starts, Will Innovative Drugs Welcome a Historic Turning Point? (Including Concept Stocks)

Sinopep expects its net profit attributable to shareholders for the first half of 2025 to be between 300 million and 330 million yuan, an increase of 32.06% to 45.27% year-on-year. The company is expanding its high-quality customer base and driving sales revenue growth of peptide raw materials through its business philosophy of "time leadership and technology leadership."

Sinopep announced a preliminary increase, expecting a net profit attributable to the parent company of 300 million to 330 million yuan for the half-year, an increase of 32.06% to 45.27% year-on-year

Vazyme and Sinopep signed a strategic cooperation agreement in Nanjing, based on a synthetic biology technology platform, combining organic synthesis and chemical processes to promote technological advancement and project cooperation. The two parties will jointly establish a biopharmaceutical company, with Vazyme holding 49% and Sinopep holding 51%

Vazyme and Sinopep signed a strategic cooperation agreement for a synthetic biology collaboration project

Sinopep(688076.SH)